Nebenwirkungen · Circadin
Circadin 2 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 4
HOS-115826 · Präparat HOS-094361
Summary of the safety profile In clinical trials (in which a total of 1,931 patients were taking Circadin and 1,642 patients were taking placebo), 48.8% of patients receiving Circadin reported an adverse reaction compared with 37.8% taking placebo. Comparing the rate of patients with adverse reactions per 100 patient weeks, the rate was higher for placebo than Circadin (5.743– placebo vs. 3.013– Circadin). The most common adverse reactions were headache, nasopharyngitis, back pain, and arthralgia, which were common, by MedDRA definition, in both the Circadin and placebo treated groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-07T15:22:00Z · SHA-256 3017f870241dac3ebcc1e9e3316286f78f9cbb94c80634571ffcb14a78331107 · Passage 55f6c022b0fea931b8ee058fbbdde41ac625f66d49a6c37710313129b37d6c41 · Zeichen 0–592 im Abschnitt